Helping us establish the Resitu technology – Investors
With support from our investors, the Resitu technology has the potential to become the globally preferred method to manage breast cancer.
Based on an invention by surgeon Per Hedén
The Resitu technology for minimally invasive surgery is built on a patented invention by surgeon Per Hedén. The first product is under development and the second-generation product is planned to establish the Resitu technology as the preferred method to treat small tumours of the breast.
Preparing for launch
Resitu Medical plans to launch the first product in the EU and later in the US. The first line of products will focus on biopsy and breast tissue removal. Preclinical studies are ongoing and clinical validations are planned for CE marking of the first instrument.
Major shareholders
In 2021-2022 Resitu Medical raised seed capital to reach the final product design and to start serial production to perform clinical trials towards CE mark and FDA clearance for our first product. Our major shareholders are Novoaim (63%), ALMI Invest Stockholm (13%) and STOAF (13%).
